The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT04217135
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose diagnostic
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT04217135
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT04217135. Randomized; no masking; primary purpose diagnostic. Start 2017-01-01 (actual); primary completion 2022-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
- Condition
- Systolic Heart Failure Stage D (Disorder)
- Condition
- Mitral Regurgitation
- Intervention (Drug)
- evidence-based medications vs. high-dose hydralazine + evidence-based medications
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Collaborator
- E-DA Hospital
Record details
- Record id
cardio:ct-nct04217135- Content hash
4eee860b0c5f63a5cb2df0c5337719aaf5d6484f0b9eff9d40cb0c0f2eb7d963